Drug class
Antiseizure medicine; voltage-gated sodium-channel modulator
Mechanism of action
The active metabolite inhibits voltage-gated sodium channels, stabilising the inactivated state and reducing sustained repetitive neuronal firing. CYP2C19 interactions are not its primary antiseizure mechanism.
General use cases
- Adjunctive treatment of partial-onset (focal) seizures in adults and paediatric patients aged 4 years and older; monotherapy eligibility varies by product and jurisdiction
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
